Does Clomid cause gynaecomastia? It is a clinically important question for any man taking clomifene citrate, whether under specialist supervision or otherwise. Clomid (clomifene citrate) is a selective oestrogen receptor modulator (SERM) licensed in the UK for female fertility, but used off-label in men to raise testosterone. Whilst it can boost testosterone levels, the resulting increase in aromatisation may elevate oestradiol, potentially triggering breast tissue changes. This article explains the hormonal mechanism, the evidence for risk, individual susceptibility factors, how to recognise symptoms, and what management options are available under UK clinical guidance.

How Clomid Works and Its Effects on Hormone Levels

Clomifene blocks hypothalamic oestrogen receptors, increasing LH and FSH, which raises testosterone in men; however, elevated testosterone undergoes aromatisation to oestradiol, which can increase gynaecomastia risk.

Clomid (clomifene citrate) is a selective oestrogen receptor modulator (SERM) licensed in the UK for stimulating ovulation in women with fertility difficulties. In men, it is used off-label — a use that is not approved by the MHRA and should only be undertaken under specialist supervision (for example, by an endocrinologist, urologist, or fertility specialist) with appropriate baseline and follow-up monitoring.

Clomifene works by blocking oestrogen receptors in the hypothalamus, which leads the brain to perceive low oestrogen levels. In response, the hypothalamus releases more gonadotropin-releasing hormone (GnRH), stimulating the pituitary gland to produce luteinising hormone (LH) and follicle-stimulating hormone (FSH). In men, elevated LH signals the testes to produce more testosterone.

Whilst this mechanism can raise testosterone levels, it does not eliminate oestrogen from the body. As testosterone rises, a proportion is naturally converted into oestradiol (a form of oestrogen) through a process called aromatisation. The extent of this conversion varies between individuals. Although clomifene blocks certain oestrogen receptors, circulating oestradiol levels may still increase — and this hormonal shift is central to understanding the potential risk of gynaecomastia. Monitoring hormone levels (including testosterone, oestradiol, LH, and FSH) is therefore an important part of safe clinical management, with dose adjustments guided by the testosterone-to-oestradiol ratio and clinical response.

For authoritative product information, refer to the clomifene citrate Summary of Product Characteristics (SmPC) available via the electronic Medicines Compendium (emc).

The Link Between Clomid and Gynaecomastia

Gynaecomastia is mechanistically plausible with clomifene use in men due to increased aromatisation of testosterone to oestradiol, and has been reported clinically, though robust incidence data are lacking.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — occurs when the balance between oestrogen and testosterone shifts in favour of oestrogen. Given clomifene's complex effects on the hormonal axis, it is reasonable to ask: does Clomid cause gynaecomastia?

Gynaecomastia has been reported in men taking clomifene, and the mechanism is plausible: as testosterone rises, increased aromatisation can elevate oestradiol, which may stimulate glandular breast tissue growth. However, the precise incidence in men is not well established, as most available evidence comes from case reports and small observational series rather than large controlled trials — reflecting the off-label nature of clomifene use in men.

It is worth noting that clomifene is itself a SERM and does block oestrogen receptors in certain tissues. However, its receptor-blocking activity is tissue-selective and does not fully protect breast tissue in all individuals. The UK SmPC for clomifene citrate (emc) describes adverse reactions in the licensed (female) indication; adverse effects in men using it off-label are less formally characterised, and any claim that regulatory bodies have specifically listed gynaecomastia as a recognised adverse effect in men should be interpreted with caution.

In summary, the risk of gynaecomastia with clomifene in men is mechanistically plausible and clinically reported, but the evidence base is limited. The likelihood depends on individual hormonal responses, aromatase activity, dosage, and duration of treatment. For further information, NICE CKS Gynaecomastia and the NHS Gynaecomastia pages provide useful UK patient-facing guidance.

Risk Factors That May Increase Your Likelihood

High aromatase activity, higher doses, prolonged use, obesity, liver or thyroid disease, and concurrent use of implicated medicines all increase the likelihood of developing gynaecomastia during clomifene treatment.

Not all men taking clomifene will develop gynaecomastia, and several factors may influence individual susceptibility. It is helpful to distinguish between factors that increase the general risk of gynaecomastia and those more specific to clomifene use.

Clomifene-specific factors:

• High aromatase activity: Some individuals naturally convert more testosterone to oestradiol, leading to a greater oestrogenic effect even when testosterone levels are elevated.

• Higher doses or prolonged use: Greater cumulative hormonal exposure increases the potential for oestrogen-driven breast tissue changes.

General risk factors for gynaecomastia (per NICE CKS and NHS guidance):

• Obesity: Excess adipose tissue increases aromatase activity, raising oestradiol levels independently of any medication.

• Liver disease or thyroid dysfunction: These conditions can alter oestrogen metabolism and increase vulnerability.

• Concurrent medicines: A number of drugs are associated with gynaecomastia, including anabolic steroids, spironolactone, anti-androgens, some antipsychotics, cimetidine, and certain other medicines. Patients should discuss all current medications and supplements with their clinician, as interactions may compound the risk. For a comprehensive list of implicated medicines, refer to the BNF or NICE CKS Gynaecomastia.

• Specific underlying conditions: Conditions such as Klinefelter syndrome, hypogonadism, or testicular tumours are associated with hormonal imbalances that predispose to gynaecomastia.

• Age: Adolescents and older men may be more susceptible due to naturally occurring hormonal shifts at these life stages.

Because clomifene is not licensed by the MHRA for use in men in the UK, its use in male patients is off-label. This underscores the importance of careful clinical oversight, including baseline and follow-up hormone testing, when it is prescribed in this context.

Recognising Symptoms and When to Seek Medical Advice

Key symptoms include a firm lump beneath the nipple, breast tenderness, and swelling; urgent GP assessment is needed for hard or irregular masses, skin changes, or nipple retraction per NICE NG12.

Gynaecomastia can present in a variety of ways, and early recognition is important for timely management. Men taking clomifene should be aware of the following signs:

Common symptoms of gynaecomastia include:

• A firm or rubbery lump of tissue beneath one or both nipples

• Breast tenderness or sensitivity, particularly around the areola

• Swelling or a feeling of fullness in the chest area

• Nipple discharge (less common, but warrants prompt assessment)

It is important to distinguish gynaecomastia from pseudogynaecomastia, which refers to fatty tissue accumulation in the chest without true glandular enlargement — a distinction that a clinician can usually make through physical examination.

You should contact your GP or prescribing specialist promptly if you notice:

• Any new lump or swelling in the breast area

• Persistent or worsening breast pain

• Nipple discharge of any kind

• Rapid or asymmetrical breast growth

Features that may suggest a more serious cause and require urgent assessment include: a hard or irregular mass, skin changes (such as dimpling or redness), nipple retraction, or swollen lymph nodes in the armpit. In line with NICE NG12 (Suspected Cancer: Recognition and Referral), your GP should refer you urgently — typically via the two-week wait pathway — if any of these features are present, to exclude rare but serious conditions such as male breast cancer or testicular tumours, which can also present with gynaecomastia.

When assessing gynaecomastia, a clinician will typically examine the testes as well as the breasts, and may arrange blood tests including beta-hCG, prolactin, testosterone, LH, FSH, oestradiol, thyroid function tests (TFTs), and liver function tests (LFTs), alongside appropriate imaging, depending on clinical findings.

Do not delay seeking advice in the hope that symptoms will resolve on their own.

Managing Gynaecomastia During or After Treatment

Dose reduction or stopping clomifene is the first-line intervention; tamoxifen or aromatase inhibitors may be used off-label under specialist supervision, and surgery is reserved for persistent or distressing cases.

If gynaecomastia develops during clomifene treatment, the first step is usually to review the treatment with the prescribing clinician. In many cases, dose reduction or discontinuation of clomifene may lead to gradual resolution of breast tissue changes, particularly if the condition is identified early — ideally within six to twelve months of onset, before fibrous tissue has had time to form. Once fibrosis is established, spontaneous resolution becomes less likely.

Management options may include:

• Dose adjustment or cessation: Reducing or stopping clomifene is often the most straightforward intervention, allowing hormone levels to normalise.

• Medical therapy — tamoxifen or aromatase inhibitors: Tamoxifen (another SERM with stronger anti-oestrogenic activity at breast tissue) and aromatase inhibitors such as anastrozole have been used to treat gynaecomastia. Both approaches are off-label for this indication, evidence is limited, and they should only be initiated and monitored by a specialist. Tamoxifen may be more effective than aromatase inhibitors for painful, recent-onset gynaecomastia. Medical therapy is most likely to be beneficial when started early, before fibrotic change occurs.

• Watchful waiting: For mild, early-stage gynaecomastia, a period of observation may be appropriate, particularly if the causative agent has been withdrawn.

• Surgical intervention: In cases where gynaecomastia is persistent, painful, or causing significant psychological distress, surgical options such as subcutaneous mastectomy may be considered. NHS funding for this procedure varies by Integrated Care Board (ICB) region and is generally reserved for cases where conservative management has failed and there is documented functional or psychological impact.

Psychological impact should not be underestimated. Gynaecomastia can affect body image and self-esteem, and patients experiencing distress should be offered appropriate support alongside physical treatment.

For further guidance on management options, refer to NICE CKS Gynaecomastia and the NHS Gynaecomastia treatment pages.

Talking to Your GP or Specialist About Your Concerns

Discuss any physical changes, request a full hormone panel, and disclose all medications; suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Open communication with your GP or specialist is essential if you are taking clomifene and have concerns about gynaecomastia or other hormonal side effects. Because clomifene is used off-label in men in the UK, it may be prescribed by a urologist, endocrinologist, or fertility specialist rather than a GP — and it is important to know who is overseeing your care.

When speaking to your doctor, it may be helpful to:

• Describe any physical changes you have noticed, including when they started and whether they are worsening

• Ask for a review of your current hormone levels — a full evaluation may include testosterone, oestradiol, LH, FSH, prolactin, beta-hCG, sex hormone-binding globulin (SHBG), thyroid function, and liver function, alongside a clinical examination of the breasts and testes

• Discuss whether your current dose is appropriate and whether any adjustments are warranted

• Ask about the risks and benefits of continuing treatment versus exploring alternative approaches

• Enquire about referral to an endocrinologist or breast clinic if symptoms are significant

Your GP can also help coordinate care if you are being managed by a specialist, and can refer you for further investigations such as ultrasound or blood tests if needed. Be candid about any other medications or supplements you are taking, as these may interact with clomifene or independently affect hormone levels.

If you believe you have experienced a side effect from clomifene, you can report it directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting suspected adverse drug reactions helps the MHRA monitor the safety of medicines used in the UK.

Finally, if you have sourced clomifene without a prescription — which does occur, particularly in fitness and bodybuilding communities — it is strongly advisable to seek medical supervision. Unmonitored use carries significant risks, including hormonal imbalance, cardiovascular effects, and the very gynaecomastia you may be hoping to avoid. Your GP will not judge you for disclosing this; their priority is your safety and wellbeing.

Frequently Asked Questions